Prosight Management, LP Immuneering Corp Transaction History
Prosight Management, LP
- $372 Million
- Q3 2024
A detailed history of Prosight Management, LP transactions in Immuneering Corp stock. As of the latest transaction made, Prosight Management, LP holds 190,000 shares of IMRX stock, worth $328,700. This represents 0.13% of its overall portfolio holdings.
Number of Shares
190,000
Previous 550,000
65.45%
Holding current value
$328,700
Previous $704,000
32.81%
% of portfolio
0.13%
Previous 0.22%
Shares
2 transactions
Others Institutions Holding IMRX
# of Institutions
41Shares Held
4.64MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.07MShares$1.85 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD810KShares$1.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$922,7190.0% of portfolio
-
Morgan Stanley New York, NY449KShares$777,3080.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny246KShares$426,0470.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $45.7M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...